Literature DB >> 21343459

Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT.

Adele M Lehane1, Donelly A van Schalkwyk, Stephanie G Valderramos, David A Fidock, Kiaran Kirk.   

Abstract

Mutant forms of the Plasmodium falciparum chloroquine resistance transporter (PfCRT) mediate chloroquine resistance by effluxing the drug from the parasite's digestive vacuole, the acidic organelle in which chloroquine exerts its parasiticidal effect. However, different parasites bearing the same mutant form of PfCRT can vary substantially in their chloroquine susceptibility. Here, we have investigated the biochemical basis for the difference in chloroquine response among transfectant parasite lines having different genetic backgrounds but bearing the same mutant form of PfCRT. Despite showing significant differences in their chloroquine susceptibility, all lines with the mutant PfCRT showed a similar chloroquine-induced H+ leak from the digestive vacuole, indicative of similar rates of PfCRT-mediated chloroquine efflux. Furthermore, all lines showed similarly reduced levels of drug accumulation. Factors other than chloroquine efflux and accumulation therefore influence the susceptibility to this drug in parasites expressing mutant PfCRT. Furthermore, in some but not all strains bearing mutant PfCRT, the 50% inhibitory concentration (IC50) for chloroquine and the degree of resistance compared to that of recombinant control parasites varied with the length of the parasite growth assays. In these parasites, the 50% inhibitory concentration for chloroquine measured in 72- or 96-h assays was significantly lower than that measured in 48-h assays. This highlights the importance of considering the first- and second-cycle activities of chloroquine in future studies of parasite susceptibility to this drug.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343459      PMCID: PMC3088201          DOI: 10.1128/AAC.01167-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.

Authors:  M B Reed; K J Saliba; S R Caruana; K Kirk; A F Cowman
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

2.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.

Authors:  D A Fidock; T Nomura; A K Talley; R A Cooper; S M Dzekunov; M T Ferdig; L M Ursos; A B Sidhu; B Naudé; K W Deitsch; X Z Su; J C Wootton; P D Roepe; T E Wellems
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

Review 3.  Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance.

Authors:  Patrick G Bray; Rowena E Martin; Leann Tilley; Stephen A Ward; Kiaran Kirk; David A Fidock
Journal:  Mol Microbiol       Date:  2005-04       Impact factor: 3.501

4.  Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine.

Authors:  Juliana Martha Sá; Olivia Twu; Karen Hayton; Sahily Reyes; Michael P Fay; Pascal Ringwald; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

Review 5.  Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum.

Authors:  Donelly A van Schalkwyk; Timothy J Egan
Journal:  Drug Resist Updat       Date:  2006-10-24       Impact factor: 18.500

6.  Acidification of the malaria parasite's digestive vacuole by a H+-ATPase and a H+-pyrophosphatase.

Authors:  Kevin J Saliba; Richard J W Allen; Stephanie Zissis; Patrick G Bray; Stephen A Ward; Kiaran Kirk
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

7.  PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.

Authors:  Patrick G Bray; Mathirut Mungthin; Ian M Hastings; Giancarlo A Biagini; Dauda K Saidu; Viswanathan Lakshmanan; David J Johnson; Ruth H Hughes; Paul A Stocks; Paul M O'Neill; David A Fidock; David C Warhurst; Stephen A Ward
Journal:  Mol Microbiol       Date:  2006-08-31       Impact factor: 3.501

8.  Reversal of chloroquine resistance in Plasmodium falciparum by verapamil.

Authors:  S K Martin; A M Oduola; W K Milhous
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

9.  A verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasites.

Authors:  Adele M Lehane; Rhys Hayward; Kevin J Saliba; Kiaran Kirk
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

10.  Digestive-vacuole genesis and endocytic processes in the early intraerythrocytic stages of Plasmodium falciparum.

Authors:  Nurhidanatasha Abu Bakar; Nectarios Klonis; Eric Hanssen; Cherrine Chan; Leann Tilley
Journal:  J Cell Sci       Date:  2010-01-12       Impact factor: 5.285

View more
  10 in total

1.  Degrees of chloroquine resistance in Plasmodium - is the redox system involved?

Authors:  Adele M Lehane; Christopher A McDevitt; Kiaran Kirk; David A Fidock
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12-01       Impact factor: 4.077

Review 2.  PfCRT and its role in antimalarial drug resistance.

Authors:  Andrea Ecker; Adele M Lehane; Jérôme Clain; David A Fidock
Journal:  Trends Parasitol       Date:  2012-09-25

3.  Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.

Authors:  Rowena E Martin; Alice S Butterworth; Donald L Gardiner; Kiaran Kirk; James S McCarthy; Tina S Skinner-Adams
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

4.  Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials.

Authors:  Adelaide S M Dennis; Adele M Lehane; Melanie C Ridgway; John P Holleran; Kiaran Kirk
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  Molecular markers in plasmodium falciparum linked to resistance to anti-malarial drugs in samples imported from Africa over an eight-year period (2002-2010): impact of the introduction of artemisinin combination therapy.

Authors:  Aranzazu Amor; Carlos Toro; Amalia Fernández-Martínez; Margarita Baquero; Agustín Benito; Pedro Berzosa
Journal:  Malar J       Date:  2012-03-30       Impact factor: 2.979

6.  Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.

Authors:  Leila S Ross; Satish K Dhingra; Sachel Mok; Tomas Yeo; Kathryn J Wicht; Krittikorn Kümpornsin; Shannon Takala-Harrison; Benoit Witkowski; Rick M Fairhurst; Frederic Ariey; Didier Menard; David A Fidock
Journal:  Nat Commun       Date:  2018-08-17       Impact factor: 14.919

7.  Uptake of a fluorescently tagged chloroquine analogue is reduced in CQ-resistant compared to CQ-sensitive Plasmodium falciparum parasites.

Authors:  Sarah J Reiling; Petra Rohrbach
Journal:  Malar J       Date:  2019-10-07       Impact factor: 2.979

8.  Structural polymorphism in the promoter of pfmrp2 confers Plasmodium falciparum tolerance to quinoline drugs.

Authors:  Sachel Mok; Kek-Yee Liong; Eng-How Lim; Ximei Huang; Lei Zhu; Peter Rainer Preiser; Zbynek Bozdech
Journal:  Mol Microbiol       Date:  2014-01-23       Impact factor: 3.501

9.  Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.

Authors:  M Isabel Veiga; Satish K Dhingra; Philipp P Henrich; Judith Straimer; Nina Gnädig; Anne-Catrin Uhlemann; Rowena E Martin; Adele M Lehane; David A Fidock
Journal:  Nat Commun       Date:  2016-05-18       Impact factor: 14.919

10.  Chloroquine exposure triggers distinct cellular responses in sensitive versus resistant Plasmodium falciparum parasites.

Authors:  Sarah J Reiling; Georg Krohne; Oliver Friedrich; Timothy G Geary; Petra Rohrbach
Journal:  Sci Rep       Date:  2018-07-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.